Human immunodeficiency virus (HIV) afflicts an estimated 30 million people globally, making it a continuing pandemic. Despite major research efforts, the rate of new infections has remained relatively static over time. This article reviews an emerging strategy for the treatment of HIV, the inhibition of the co-receptors necessary for HIV entry, CCR5 and CXCR4. The aim of this article is to highlight potential therapeutics derived from peptides and proteins that show particular promise in HIV treatment. Molecules that act on CCR5, CXCR4 or on both receptors will be discussed herein.
AshkenaziAWexler-CohenYShaiY. Multifaceted action of Fuzeon as virus–cell membrane fusion inhibitor. BBA – Biomembranes2010; 1808: 1–7.
4.
GilliamBLRiedelDJRedfieldRR. Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med2011; 9: S9–S9.
5.
FengYBroderCCKennedyPEBergerEA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science1996; 272: 872–7.
6.
DengHLiuREllmeierWChoeSUnutmazDBurkhartMDi MarziPMarmonSSuttonREHillCMDavisCBPeiperSCSchallTJLittmanDRLandauNR. Identification of a major co-receptor for primary isolates of HIV-1. Nature1996; 381: 661–6.
7.
AlkhatibGCombadiereCBroderCCFengYKennedyPEMurphyPMBergerEA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science1996; 272: 1955–8.
8.
DragicTLitwinVAllawayGPMartinSRHuangYNagashimaKACayananCMaddonPJKoupRAMooreJPPaxtonWA. HIV-1 entry into CD4 + cells is mediated by the chemokine receptor CC-CKR-5. Nature1996; 381: 667–73.
9.
SamsonMLibertFDoranzBJRuckerJLiesnardCFarberCMSaragostiSLapoumeroulieCCognauxJForceilleCMuyldermansGVerhofstedeCBurtonboyGGeorgesMImaiTRanaSYiYSmythRJ CollmanRGDomsRWVassartGParmentierM. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature1996; 382: 722–5.
10.
DeanMCarringtonMWinklerCHuttleyGASmithMWAllikmetsRGoedertJJBuchbinderSPVittinghoffEGompertsEDonfieldSVlahovDKaslowRSaahARinaldoCDetelsRO'BrienSJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science1996; 273: 1856–62.
11.
LiuRPaxtonWAChoeSCeradiniDMartinSRHorukRMacDonaldMEStuhlmannHKoupRALandauNR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell1996; 86: 367–77.
12.
PopeMHaaseAT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med2003; 9: 847–52.
13.
BrummeZLGoodrichJMayerHBBrummeCJHenrickBMWynhovenBAsselinJJCheungPKHoggRSMontanerJSG. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis2005; 192: 466–74.
14.
NelAMCoplanPSmytheSCMcCordKMitchnickMKapturPERomanoJ. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses2010; 26: 1181–90.
15.
NelAMSmytheSCHabibiSKapturPERomanoJW. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr2010; 55: 161–9.
16.
NelASmytheSYoungKMalcolmKMcCoyCRosenbergZRomanoJ. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr2009; 51: 416–23.
17.
SelhorstPVazquezACTerrazas-ArandaKMichielsJVereeckenKHeyndrickxLWeberJQuiñones-MateuMEAriënKKVanhamG. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother2011; 55: 1403–13.
18.
NedellecRCoetzerMLedermanMMOffordREHartleyOMosierDE. “Resistance” to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance. J Virol2010; 84: 5842–5.
19.
NedellecRCoetzerMLedermanMMOffordREHartleyOMosierDE. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. PLoS ONE2011; 6: e22020–e22020.
20.
GibsonRMArtsEJ. Past, present, and future of entry inhibitors as HIV microbicides. Curr HIV Res2012; 10: 19–26.
21.
HenrichTJKuritzkesDR. HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol2013; 3: 51–57.
22.
CocchiFDeVicoALGarzino-DemoAAryaSKGalloRCLussoP. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8 + T cells. Science1995; 270: 1811–15.
23.
Arenzana-SeisdedosFVirelizierJLRoussetDClark-LewisILoetscherPMoserBBaggioliniM. HIV blocked by chemokine antagonist. Nature1996; 383: 400–400.
24.
MoriuchiHMoriuchiMCombadiereCMurphyPMFauciAS. CD8 + T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci USA1996; 93: 15341–5.
25.
KinterACatanzaroAMonacoJRuizMJustementJMoirSArthosJOlivaAEhlerLMizellSJacksonROstrowskiMHoxieJOffordRFauciAS. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4( + ) T cells: role of signal transduction. Proc Natl Acad Sci USA1998; 95: 11880–5.
26.
ChoiWTNedellecRCoetzerMColinPLaganeBOffordREHartleyOMosierDE. CCR5 Mutations Distinguish N-terminal Modifications of RANTES (CCL5) with Agonist versus Antagonist Activity. J Virol2012; 86: 10218–10220.
27.
HartleyOOffordRE. Engineering chemokines to develop optimized HIV inhibitors. Curr Protein Pept Sci2005; 6: 207–19.
28.
VangelistaLSecchiMLussoP. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine2008; 26: 3008–15.
29.
ProudfootAEPowerCAHoogewerfAJMontjoventMOBorlatFOffordREWellsTN. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem1996; 271: 2599–603.
30.
MackMLuckowBNelsonPJCihakJSimmonsGClaphamPRSignoretNMarshMStangassingerMBorlatFWellsTNSchlöndorffDProudfootAE. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med1998; 187: 1215–24.
31.
WilkenJHooverDThompsonDABarlowPNMcSparronHPicardLWlodawerALubkowskiJKentSB. Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES. Chem Biol1999; 6: 43–51.
32.
HartleyOGaertnerHWilkenJThompsonDFishRRamosAPastoreCDufourBCeriniFMelottiAHevekerNPicardLAlizonMMosierDKentSOffordR. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA2004; 101: 16460–5.
33.
LedermanMMVeazeyRSOffordRMosierDEDufourJMeffordMPiatakMLifsonJDSalkowitzJRRodriguezBBlauveltAHartleyO. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science2004; 306: 485–7.
34.
KawamuraTBruseSEAbrahaASugayaMHartleyOOffordREArtsEJZimmermanPABlauveltA. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol2004; 78: 7602–9.
CeriniFLandayAGichingaCLedermanMMFlycktRStarksDOffordRELe GalFHartleyO. Chemokine analogues show suitable stability for development as microbicides. J Acquir Immune Defic Syndr2008; 49: 472–6.
37.
GaertnerHOffordRBottiPKuenziGHartleyO. Semisynthetic Analogues of PSC-RANTES, a Potent Anti-HIV Protein. Bioconjug Chem2008; 19: 480–9.
KiickKLSaxonETirrellDABertozziCR. Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. Proc Natl Acad Sci USA2002; 99: 19–24.
NardeseVLonghiRPoloSSironiFArcelloniCParoniRDeSantisCSarmientosPRizziMBolognesiMPavoneVLussoP. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat Struct Mol Biol2001; 8: 611–15.
42.
VangelistaLLonghiRSironiFPavoneVLussoP. Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity. Biochem Biophys Res Commun2006; 351: 664–8.
43.
SecchiMLonghiRVassenaLSironiFGrzesiekSLussoPVangelistaL. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides. Chem Biol2012; 19: 1579–88.
44.
HartleyODorghamKPerez-BercoffDCeriniFHeimannAGaertnerHOffordREPancinoGDebrePGorochovG. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J Virol2003; 77: 6637–44.
45.
VyroubalovaECHartleyOMermodNFischI. Identification of peptide ligands to the chemokine receptor CCR5 and their maturation by gene shuffling. Mol Immunol2006; 43: 1573–8.
46.
WangFYZhangTYLuoJXHeGAGuQLXiaoF. Selection of CC chemokine receptor 5-binding peptide from a phage display peptide library. Biosci Biotechnol Biochem2006; 70: 2035–41.
47.
WuYDengRWuW. Study on CCR5 analogs and affinity peptides. Protein Eng Des Sel2012; 25: 97–105.
48.
PatelKDixitVDLeeJHKimJWSchafferEMNguyenDTaubDD. The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist. Int J Med Sci2012; 9: 51–8.
49.
ProudfootAEFritchleySBorlatFShawJPVilboisFZwahlenCTrkolaAMarchantDClaphamPRWellsTN. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem2001; 276: 10620–6.
50.
CzaplewskiLGMcKeatingJCravenCJHigginsLDAppayVBrownADudgeonTHowardLAMeyersTOwenJPalanSRTanPWilsonGWoodsNRHeyworthCMLordBIBrothertonDChristisonRCraigSCribbesSEdwardsRMEvansSJGilbertRMorganPRandleESchofieldNVarleyPGFisherJWalthoJPHunterMG. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem1999; 274: 16077–84.
51.
TrkolaAGordonCMatthewsJKetasTCzaplewskiLProudfootAEMooreJP. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J Virol1999; 73: 6370–9.
52.
HamASCostMRSassiABDezzuttiCSRohanLC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res2009; 26: 502–11.
53.
WangNXOffordRHartleyOLedermanMRecum vonHA. Controlled release of RANTES analogues using heparin affinity. Mol Pharm, in press.
54.
WangNXRecum vonHA. Affinity-based drug delivery. Macromol Biosci2010; 11: 321–32.
55.
ShaoHCrnogoracMMKongTChenS-YWilliamsJMTackJMGueriguianVCagleENCarnevaliMTumeltyDPaliardXMirandaLPBradburneJAKochendoerferGG. Site-specific polymer attachment to a CCL-5 (RANTES) analogue by oxime exchange. J Am Chem Soc2005; 127: 1350–1.
56.
DongCZTianSMadaniNChoiWTKumarSLiuDSodroskiJGHuangZ. Role of CXCR4 internalization in the anti-HIV activity of stromal cell-derived factor-1 probed by a novel synthetically and modularly modified-chemokine analog. Exp Biol Med2011; 236: 1413–19.
57.
WuBChienEYTMolCDFenaltiGLiuWKatritchVAbagyanRBroounAWellsPBiFCHamelDJKuhnPHandelTMCherezovVStevensRC. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science2010; 330: 1066–71.
58.
PlanesasJMPérez-NuenoVIBorrellJITeixidóJ. Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors. J Mol Graph Model2012; 38: 123–36.
59.
OberlinEAmaraABachelerieFBessiaCVirelizierJLArenzana-SeisdedosFSchwartzOHeardJMClark-LewisILeglerDFLoetscherMBaggioliniMMoserB. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature1996; 382: 833–5.
60.
BleulCCFarzanMChoeHParolinCClark-LewisISodroskiJSpringerTA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature1996; 382: 829–33.
61.
LiangX. CXCR4, inhibitors and mechanisms of action. Chem Biol Drug Des2008; 72: 97–110.
62.
AboyeTLHaHMajumderSChristFDebyserZShekhtmanANeamatiNCamareroJA. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem2012; 55: 10729–34.
63.
GarciaAECamareroJA. Biological activities of natural and engineered cyclotides, a novel molecular scaffold for peptide-based therapeutics. Curr Mol Pharmacol2010; 3: 153–63.
64.
CraikDJConibearAC. The chemistry of cyclotides. J Org Chem2011; 76: 4805–17.
65.
KimuraRHMiaoZChengZGambhirSSCochranJR. A dual-labeled knottin peptide for pet and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem2010; 21: 436–44.
66.
KimuraRHLevinAMCochranFVCochranJR. Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins2009; 77: 359–69.
67.
Tamamura H, Omagari A, Oishi S, Kanamoto T, Yamamoto N, Peiper SC, Nakashima H, Otaka A, Fujii N. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg Med Chem Lett 2000;10:2633–2637.
68.
TamamuraHSugiokaMOdagakiYKanYOishiSNakashimaHYamamotoNPeiperSCHamanakaN. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg Med Chem Lett2001; 11: 359–62.
69.
FujiiNOishiSHiramatsuKArakiTUedaSTamamuraHOtakaAKusanoSTerakuboSNakashimaHBroachJATrentJOWangZ-XPeiperSC. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew Chem Int Edit2003; 42: 3251–3.
70.
NarumiTHayashiRTomitaKKobayashiKTanaharaNOhnoHNaitoTKodamaEMatsuokaMOishiSFujiiN. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. Org Biomol Chem2010; 8: 616–616.
71.
TamamuraHArakiTUedaSWangZOishiSEsakaATrentJONakashimaHYamamotoNPeiperSCOtakaAFujiiN. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem2005; 48: 3280–9.
72.
UedaSOishiSWangZ-XArakiTTamamuraHCluzeauJOhnoHKusanoSNakashimaHTrentJOPeiperSCFujiiN. Structure–activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J Med Chem2007; 50: 192–8.
73.
InokuchiEOishiSKuboTOhnoHShimuraKMatsuokaMFujiiN. Potent CXCR4 antagonists containing amidine type peptide bond isosteres. ACS Med Chem Lett2011; 2: 477–80.
74.
DemmerOFrankAOHagnFSchotteliusMMarinelliLCosconatiSBrack-WernerRKrembSWesterH-JKesslerHA. A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. Angew Chem Int Edit2012; 51: 8110–13.
75.
TanNCYuPKwonY-UKodadekT. High-throughput evaluation of relative cell permeability between peptoids and peptides. Bioorg Med Chem2008; 16: 5853–61.
76.
KwonY.-UKodadekT. Quantitative evaluation of the relative cell permeability of peptoids and peptides. J Am Chem Soc2007; 129: 1508–1508.
77.
MillerSSimonRNgSZuckermannRKerrJMoosW. Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers. Drug Dev Res1995; 35: 20–32.
78.
YoshikawaYKobayashiKOishiSFujiiNFuruyaT. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4–FC131 interactions. Bioorg Med Chem Lett2012; 22: 2146–50.
79.
JähnichenSBlanchetotCMaussangDGonzalez-PajueloMChowKYBoschLDe VriezeSSerruysBUlrichtsHVandeveldeW. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci USA2010; 107: 20565–70.
80.
ZhaoBMankowskiMKSnyderBAPtakRGLiwangPJ. Highly potent chimeric inhibitors targeting two steps of HIV cell entry. J Biol Chem2011; 286: 28370–81.
